

A

trkB mutations						
Week	10	20	25	30	35	40
[Rif] ($\mu\text{g/ml}$)	0.5	2	4	8	16	32
Line						
$\Delta nucS$ 5	A130A	A130A	A130A	A130A	A130A	A130A
$\Delta nucS$ 12	NO	NO	NO	NO	W111R	extinct
$\Delta nucS$ 18	NO	V91A	V91A	V91A	V91A	V91A
$\Delta nucS$ 20	NO	NO	NO	G12D	G12D	G12D

B

mchK mutations						
Week	10	20	25	30	35	40
[Rif] ($\mu\text{g/ml}$)	0.5	2	4	8	16	32
Line						
mc^2 4	NO	NO	NO	NO	$\Delta - 1c$	extinct
mc^2 6	NO	NO	NO	T163I	T163I	extinct
mc^2 19	NO	NO	NO	A216V	A216V	extinct
$\Delta nucS$ 1	NO	NO	NO	R120Q	R120Q	R120Q
$\Delta nucS$ 2	NO	NO	NO	NO	E316G	E316G
$\Delta nucS$ 8	NO	NO	NO	P321L	P321L	extinct
$\Delta nucS$ 9	NO	NO	V203A	V203A	V203A	V203A
$\Delta nucS$ 19	NO	NO	Q265R	Q265R	Q265R	Q265R



Figure S1. Mutations in trkB and mchK in the MA lines. **A.** Emergence of trkB mutations in the MA lines. **B.** Emergence of mchK mutations in the MA lines. Tables show the appearance of mutations in trkB and mchK in each MA line during experimental evolution (in weeks). Only MA lines with mutations in these genes are represented. Levels of rifampicin resistance of the evolved lines are indicated according to their MICs values, with the following color code: no resistance, 1 – 2 $\mu\text{g ml}^{-1}$ (grey); low, 4 – 16 $\mu\text{g ml}^{-1}$ (light red); intermediate, 32 – 128 $\mu\text{g ml}^{-1}$ (medium red); and high, 256 – 1024 $\mu\text{g ml}^{-1}$ (dark red).